3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Ovarian Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
anlotinib
2
Bevacizumab
2
trametinib
1
siltuximab
1
olaparib
1
niraparib
1
enzalutamide
1
dabrafenib
1
cobimetinib
1
atezolizumab
1
Vemurafenib
1
Papanicolaou Test
1
Human Papillomavirus DNA Tests
1
Drug Therapy
1
Colposcopy
1
CP protocol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Vemurafenib
×
Gynecologic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled